Literature DB >> 15589388

5-HT1A receptors are differentially involved in the anxiolytic- and antidepressant-like effects of 8-OH-DPAT and fluoxetine in the rat.

J De Vry1, R Schreiber, C Melon, M Dalmus, K R Jentzsch.   

Abstract

Fluoxetine, a selective serotonin reuptake inhibitor, shows moderate efficacy and potency in the rat forced swimming depression test and the shock-induced ultrasonic vocalization anxiety test, whereas the 5-HT(1A) receptor agonist (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) is highly efficient and potent in both models. Whereas the 5-HT(1A) receptor antagonist WAY 100,635 abolishes the effect of 8-OH-DPAT in both models, it only attenuates the antidepressant-like effect of fluoxetine. Pretreatment with the 5-HT-depleting agent parachlorophenylalanine attenuates the antidepressant-like effect of fluoxetine, but not that of 8-OH-DPAT. This suggests that the antidepressant-like effect of fluoxetine and 8-OH-DPAT results from indirect (via increased synaptic availability of 5-HT) and direct stimulation of postsynaptic 5-HT(1A) receptors, respectively; whereas the anxiolytic-like effect of fluoxetine is not mediated by 5-HT(1A) receptors. The data support the hypothesis that the antidepressant- and anxiolytic-like effect of 8-OH-DPAT is predominantly mediated by post- and presynaptic 5-HT(1A) receptors, respectively, and that 5-HT(1A) receptors are only partially involved in the antidepressant-like effect of fluoxetine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15589388     DOI: 10.1016/j.euroneuro.2004.01.004

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  15 in total

1.  Interactions between corticotropin-releasing factor and the serotonin 1A receptor system on acoustic startle amplitude and prepulse inhibition of the startle response in two rat strains.

Authors:  Lisa H Conti
Journal:  Neuropharmacology       Date:  2011-08-02       Impact factor: 5.250

2.  The contribution of serotonin 1A receptors to kappa opioid immunosuppression.

Authors:  M A Cheido; G V Idova
Journal:  Neurosci Behav Physiol       Date:  2009-06-11

Review 3.  Biomarkers of epileptogenesis: psychiatric comorbidities (?).

Authors:  Andres M Kanner; Andrey Mazarati; Matthias Koepp
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

4.  Ethanol induced antidepressant-like effect in the mouse forced swimming test: modulation by serotonergic system.

Authors:  Nishant S Jain; Uday Kannamwar; Lokesh Verma
Journal:  Psychopharmacology (Berl)       Date:  2016-11-12       Impact factor: 4.530

5.  Involvement of presynaptic 5-HT(1A) receptors in immunomodulation in conditions of psychoemotional tension.

Authors:  G V Idova; S M Davydova
Journal:  Neurosci Behav Physiol       Date:  2010-05-14

6.  Systemic serotonin inhibits brown adipose tissue sympathetic nerve activity via a GABA input to the dorsomedial hypothalamus, not via 5HT1A receptor activation in raphe pallidus.

Authors:  Clarissa M D Mota; Luiz G S Branco; Shaun F Morrison; Christopher J Madden
Journal:  Acta Physiol (Oxf)       Date:  2019-11-01       Impact factor: 6.311

7.  Long-term citalopram maintenance in mice: selective reduction of alcohol-heightened aggression.

Authors:  Elizabeth E Caldwell; Klaus A Miczek
Journal:  Psychopharmacology (Berl)       Date:  2007-10-20       Impact factor: 4.530

8.  Pharmacological characterisation of place escape/avoidance behaviour in the rat chronic constriction injury model of neuropathic pain.

Authors:  Louise H Pedersen; Gordon Blackburn-Munro
Journal:  Psychopharmacology (Berl)       Date:  2006-02-15       Impact factor: 4.530

9.  Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist.

Authors:  A Newman-Tancredi; J-C Martel; M-B Assié; J Buritova; E Lauressergues; C Cosi; P Heusler; L Bruins Slot; F C Colpaert; B Vacher; D Cussac
Journal:  Br J Pharmacol       Date:  2009-01-12       Impact factor: 8.739

Review 10.  Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence.

Authors:  Chi-Un Pae; Alessandro Serretti; Ashwin A Patkar; Praksh S Masand
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.